CNY 35.36
(4.15%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 806.72 Million CNY | -12.16% |
2022 | 918.39 Million CNY | -18.46% |
2021 | 1.12 Billion CNY | 6.62% |
2020 | 1.05 Billion CNY | -0.74% |
2019 | 1.06 Billion CNY | -2.69% |
2018 | 1.09 Billion CNY | 29.35% |
2017 | 845.49 Million CNY | 9.25% |
2016 | 773.89 Million CNY | 32.1% |
2015 | 585.84 Million CNY | -2.69% |
2014 | 602 Million CNY | 64.31% |
2013 | 366.39 Million CNY | 18.38% |
2012 | 309.51 Million CNY | -10.95% |
2011 | 347.55 Million CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 770.13 Million CNY | -4.54% |
2024 Q3 | 1.18 Billion CNY | 42.93% |
2024 Q2 | 831.74 Million CNY | 8.0% |
2023 FY | 806.72 Million CNY | -12.16% |
2023 Q3 | 965.52 Million CNY | 1.22% |
2023 Q2 | 953.84 Million CNY | 12.17% |
2023 Q1 | 850.35 Million CNY | -7.41% |
2023 Q4 | 806.72 Million CNY | -16.45% |
2022 Q4 | 918.39 Million CNY | -6.23% |
2022 Q3 | 979.43 Million CNY | -7.04% |
2022 Q2 | 1.05 Billion CNY | 34.24% |
2022 Q1 | 784.84 Million CNY | -30.31% |
2022 FY | 918.39 Million CNY | -18.46% |
2021 FY | 1.12 Billion CNY | 6.62% |
2021 Q3 | 1.05 Billion CNY | 5.49% |
2021 Q2 | 999.41 Million CNY | 34.51% |
2021 Q4 | 1.12 Billion CNY | 6.82% |
2021 Q1 | 743 Million CNY | -29.66% |
2020 Q4 | 1.05 Billion CNY | 15.84% |
2020 FY | 1.05 Billion CNY | -0.74% |
2020 Q2 | 896.1 Million CNY | 56.24% |
2020 Q1 | 573.55 Million CNY | -46.11% |
2020 Q3 | 911.88 Million CNY | 1.76% |
2019 Q2 | 1.06 Billion CNY | 41.77% |
2019 Q1 | 748.54 Million CNY | -31.56% |
2019 FY | 1.06 Billion CNY | -2.69% |
2019 Q4 | 1.06 Billion CNY | 10.54% |
2019 Q3 | 962.7 Million CNY | -9.28% |
2018 Q3 | 859.65 Million CNY | 13.31% |
2018 Q1 | 572.45 Million CNY | -32.29% |
2018 FY | 1.09 Billion CNY | 29.35% |
2018 Q4 | 1.09 Billion CNY | 27.22% |
2018 Q2 | 758.69 Million CNY | 32.53% |
2017 Q2 | 698.95 Million CNY | 13.3% |
2017 FY | 845.49 Million CNY | 9.25% |
2017 Q4 | 845.49 Million CNY | 6.82% |
2017 Q3 | 791.54 Million CNY | 13.25% |
2017 Q1 | 616.9 Million CNY | -20.28% |
2016 Q3 | 700 Million CNY | 9.15% |
2016 Q4 | 773.89 Million CNY | 10.56% |
2016 Q1 | 439.79 Million CNY | -24.93% |
2016 Q2 | 641.31 Million CNY | 45.82% |
2016 FY | 773.89 Million CNY | 32.1% |
2015 Q4 | 585.84 Million CNY | 0.0% |
2015 Q1 | - CNY | 0.0% |
2015 FY | 585.84 Million CNY | -2.69% |
2014 FY | 602 Million CNY | 64.31% |
2013 FY | 366.39 Million CNY | 18.38% |
2012 FY | 309.51 Million CNY | -10.95% |
2011 FY | 347.55 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Liuzhou Liangmianzhen Co., Ltd. | 505.75 Million CNY | -59.51% |
Shanghai Jahwa United Co., Ltd. | 3.76 Billion CNY | 78.568% |
Henan Rebecca Hair Products Co., Ltd. | 2.53 Billion CNY | 68.146% |
Perfect Group Corp., Ltd | 765.94 Million CNY | -5.324% |
RUNBEN BIOTECHNOLOGY | 97.61 Million CNY | -726.458% |
Proya Cosmetics Co.,Ltd. | 2.91 Billion CNY | 72.338% |
Lafang China Co.,Ltd | 195.21 Million CNY | -313.241% |
Guangdong Marubi Biotechnology Co., Ltd. | 1.02 Billion CNY | 21.604% |
Hangzhou Haoyue Personal Care Co., Ltd | 1.42 Billion CNY | 43.56% |